Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study.

D'Arcangelo M, Buonerba C, Avallone A, Dazzi C, Frassineti G, Tamberi S, Tassinari D, Aprile G, Granetto C, Bonetti A, Vecchiarelli S, Cappuzzo F.

Ann Oncol. 2019 Jul;30 Suppl 4:iv87-iv88. doi: 10.1093/annonc/mdz155.317. Epub 2019 Dec 4. No abstract available.

PMID:
32085328
2.

Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies.

Rosati G, Cordio S, Reggiardo G, Aprile G, Butera A, Avallone A, Tucci A, Novello G, Blanco G, Caputo G, Bilancia D, Bordonaro R.

Ann Oncol. 2019 Jul;30 Suppl 4:iv19-iv20. doi: 10.1093/annonc/mdz155.072. Epub 2019 Dec 4. No abstract available.

PMID:
32085072
3.

Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy.

Mauriello A, Manolio C, Cavalluzzo B, Avallone A, Borrelli M, Morabito A, Iovine E, Chambery A, Russo R, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L.

J Transl Med. 2020 Jan 23;18(1):34. doi: 10.1186/s12967-020-02218-x.

4.

Liver radiologic findings of chemotherapy-induced toxicity in liver colorectal metastases patients.

Granata V, Fusco R, Venanzio Setola S, Mattace Raso M, Avallone A, De Stefano A, Nasti G, Palaia R, Delrio P, Petrillo A, Izzo F.

Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9697-9706. doi: 10.26355/eurrev_201911_19531.

5.

Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases.

Granata V, Fusco R, Maio F, Avallone A, Nasti G, Palaia R, Albino V, Grassi R, Izzo F, Petrillo A.

Infect Agent Cancer. 2019 Nov 27;14:40. doi: 10.1186/s13027-019-0264-3. eCollection 2019.

6.

The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.

Granata V, Fusco R, Setola SV, Castelguidone ELD, Camera L, Tafuto S, Avallone A, Belli A, Incollingo P, Palaia R, Izzo F, Petrillo A.

Radiol Oncol. 2019 Oct 25;53(4):373-387. doi: 10.2478/raon-2019-0040.

7.

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer.

Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes A, Ciardiello F.

ESMO Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. eCollection 2019.

8.

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G.

BMC Cancer. 2019 Sep 9;19(1):899. doi: 10.1186/s12885-019-6109-z.

9.

Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer.

Rosati G, Addeo R, Aprile G, Avallone A, Bilancia D, Brugnatelli S, Buccafusca G, Carlomagno C, Cordio S, Delfanti S, Dell'Aquila E, Di Bisceglie M, Di Donato S, Di Stasi A, Germano D, Giuliani F, Granetto C, Latiano TP, Leo S, Tralongo P, Stroppolo ME, Venturini F, Bianco S.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1089-1096. doi: 10.1007/s00280-019-03943-x. Epub 2019 Sep 6.

PMID:
31493178
10.

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.

Ottaiano A, Capozzi M, Tafuto S, De Stefano A, De Divitiis C, Romano C, Avallone A, Nasti G.

Front Oncol. 2019 Aug 13;9:766. doi: 10.3389/fonc.2019.00766. eCollection 2019.

11.

Diagnostic performance of gadoxetic acid-enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection.

Granata V, Fusco R, de Lutio di Castelguidone E, Avallone A, Palaia R, Delrio P, Tatangelo F, Botti G, Grassi R, Izzo F, Petrillo A.

BMC Gastroenterol. 2019 Jul 24;19(1):129. doi: 10.1186/s12876-019-1036-7.

12.

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.

Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M.

Eur J Cancer. 2019 Sep;118:121-130. doi: 10.1016/j.ejca.2019.06.008. Epub 2019 Jul 19.

13.

Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials.

Rosati G, Cordio S, Reggiardo G, Aprile G, Butera A, Avallone A, Tucci A, Novello G, Blanco G, Caputo G, Bilancia D, Bordonaro R.

Cancers (Basel). 2019 Apr 24;11(4). pii: E578. doi: 10.3390/cancers11040578.

14.

18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.

Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, Silvestro L, Granata V, Bianco F, Romano C, Di Gennaro F, Budillon A, Petrillo A, Muto P, Botti G, Delrio P, Lastoria S.

J Nucl Med. 2019 Nov;60(11):1560-1568. doi: 10.2967/jnumed.118.222604. Epub 2019 Mar 15.

PMID:
30877175
15.

Unravelling the contribution of early postseismic deformation using sub-daily GNSS positioning.

Twardzik C, Vergnolle M, Sladen A, Avallone A.

Sci Rep. 2019 Feb 11;9(1):1775. doi: 10.1038/s41598-019-39038-z.

16.

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.

Fanotto V, Fornaro L, Bordonaro R, Rosati G, Rimassa L, Di Donato S, Santini D, Tomasello G, Leone F, Silvestris N, Stragliotto S, Scartozzi M, Giampieri R, Nichetti F, Antonuzzo L, Cinieri S, Avallone A, Pellegrino A, Melisi D, Vasile E, Gerratana L, Aprile G.

J Geriatr Oncol. 2019 Jul;10(4):591-597. doi: 10.1016/j.jgo.2018.11.009. Epub 2018 Dec 11.

PMID:
30551958
17.

Posterior HOX genes and HOTAIR expression in the proximal and distal colon cancer pathogenesis.

Tatangelo F, Di Mauro A, Scognamiglio G, Aquino G, Lettiero A, Delrio P, Avallone A, Cantile M, Botti G.

J Transl Med. 2018 Dec 12;16(1):350. doi: 10.1186/s12967-018-1725-y.

18.

Assessing response to neo-adjuvant therapy in locally advanced rectal cancer using Intra-voxel Incoherent Motion modelling by DWI data and Standardized Index of Shape from DCE-MRI.

Petrillo A, Fusco R, Granata V, Filice S, Sansone M, Rega D, Delrio P, Bianco F, Romano GM, Tatangelo F, Avallone A, Pecori B.

Ther Adv Med Oncol. 2018 Nov 16;10:1758835918809875. doi: 10.1177/1758835918809875. eCollection 2018.

19.

Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors.

Ottaiano A, Scotti V, De Divitiis C, Capozzi M, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Vicario V, De Stefano A, Tafuto S, Berretta M, Nasti G, Avallone A.

Oncotarget. 2018 Oct 16;9(81):35251-35265. doi: 10.18632/oncotarget.25834. eCollection 2018 Oct 16.

20.

Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples.

Capozzi M, De Divitiis C, Ottaiano A, Teresa T, Capuozzo M, Maiolino P, Botti G, Tafuto S, Avallone A; Abdominal Oncology Group.

Front Public Health. 2018 Oct 12;6:291. doi: 10.3389/fpubh.2018.00291. eCollection 2018.

21.

Diffusion and perfusion MR parameters to assess preoperative short-course radiotherapy response in locally advanced rectal cancer: a comparative explorative study among Standardized Index of Shape by DCE-MRI, intravoxel incoherent motion- and diffusion kurtosis imaging-derived parameters.

Fusco R, Sansone M, Granata V, Grimm R, Pace U, Delrio P, Tatangelo F, Botti G, Avallone A, Pecori B, Petrillo A.

Abdom Radiol (NY). 2019 Nov;44(11):3683-3700. doi: 10.1007/s00261-018-1801-z.

PMID:
30361867
22.

Morphological and functional features prognostic factor of magnetic resonance imaging in locally advanced rectal cancer.

Fusco R, Granata V, Rega D, Russo C, Pace U, Pecori B, Tatangelo F, Botti G, Izzo F, Cascella M, Avallone A, Delrio P, Petrillo A.

Acta Radiol. 2019 Jul;60(7):815-825. doi: 10.1177/0284185118803783. Epub 2018 Oct 4. No abstract available.

PMID:
30286607
23.

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram.

Pietrantonio F, Barretta F, Fanotto V, Park SH, Morano F, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G.

Oncology. 2018;95(6):344-352. doi: 10.1159/000491753. Epub 2018 Aug 21.

PMID:
30130791
24.

A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases.

Granata V, Fusco R, Avallone A, Catalano O, Piccirillo M, Palaia R, Nasti G, Petrillo A, Izzo F.

Future Oncol. 2018 Sep;14(21):2189-2206. doi: 10.2217/fon-2018-0080. Epub 2018 Aug 7. Review.

PMID:
30084273
25.

DCE-MRI time-intensity curve visual inspection to assess pathological response after neoadjuvant therapy in locally advanced rectal cancer.

Petrillo A, Fusco R, Petrillo M, Granata V, Bianco F, Di Marzo M, Delrio P, Tatangelo F, Botti G, Pecori B, Avallone A.

Jpn J Radiol. 2018 Oct;36(10):611-621. doi: 10.1007/s11604-018-0760-1. Epub 2018 Jul 23.

PMID:
30039258
26.

The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress.

Ziranu P, Demurtas L, Puzzoni M, Loupakis F, Daniele B, Rimassa L, Bilancia D, Lonardi S, Avallone A, Pella N, Ferrari D, Frassineti L, Beretta G, Zaniboni A, Santoro A, Zampino M, Sarobba M, Zagonel V, Barni S, Palmieri G, Labianca R, Cascinu S, Scartozzi M.

Ann Oncol. 2018 Jun;29 Suppl 5:v82. doi: 10.1093/annonc/mdy151.290. Epub 2020 Jan 7. No abstract available.

27.

Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).

Avallone A, Nasti G, Rosati G, Carlomagno C, Romano C, Bilancia D, De Stefano A, Silvestro L, Ottaiano A, Cassata A, Bianco F, Izzo F, Delrio P, De Gennaro E, Casaretti R, Tafuto S, Albino V, Pace U, Lastoria S, Gallo C, Budillon A, Piccirillo M.

Ann Oncol. 2018 Jun;29 Suppl 5:v74. doi: 10.1093/annonc/mdy151.262. Epub 2020 Jan 7. No abstract available.

28.

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.

Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A.

Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Review.

29.

Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?

Ottaiano A, Cassata A, Capozzi M, De Divitiis C, De Stefano A, Avallone A.

Front Oncol. 2018 Mar 14;8:62. doi: 10.3389/fonc.2018.00062. eCollection 2018.

30.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum. No abstract available.

31.

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.

PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018.

32.

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.

Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, Muto P, Delrio P, Avallone A, Budillon A, Di Gennaro E.

J Exp Clin Cancer Res. 2017 Dec 6;36(1):177. doi: 10.1186/s13046-017-0647-5.

33.

Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy.

Ottaiano A, Napolitano M, Capozzi M, Tafuto S, Avallone A, Scala S.

World J Clin Cases. 2017 Nov 16;5(11):390-396. doi: 10.12998/wjcc.v5.i11.390.

34.

MR imaging perfusion and diffusion analysis to assess preoperative Short Course Radiotherapy response in locally advanced rectal cancer: Standardized Index of Shape by DCE-MRI and intravoxel incoherent motion-derived parameters by DW-MRI.

Petrillo A, Fusco R, Granata V, Setola SV, Sansone M, Rega D, Delrio P, Bianco F, Romano GM, Tatangelo F, Avallone A, Pecori B.

Med Oncol. 2017 Nov 18;34(12):198. doi: 10.1007/s12032-017-1059-2.

PMID:
29151142
35.

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G.

Future Oncol. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. Erratum in: Future Oncol. 2018 Mar;14 (6):577.

PMID:
28976226
36.

Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows.

Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A.

Oncotarget. 2017 Apr 19;8(31):51224-51237. doi: 10.18632/oncotarget.17227. eCollection 2017 Aug 1.

37.

Near-source high-rate GPS, strong motion and InSAR observations to image the 2015 Lefkada (Greece) Earthquake rupture history.

Avallone A, Cirella A, Cheloni D, Tolomei C, Theodoulidis N, Piatanesi A, Briole P, Ganas A.

Sci Rep. 2017 Sep 4;7(1):10358. doi: 10.1038/s41598-017-10431-w.

38.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2017 Dec;22(12):1463-1469. doi: 10.1634/theoncologist.2017-0158. Epub 2017 Aug 31. Erratum in: Oncologist. 2018 Feb;23 (2):272.

39.

FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.

Ottaiano A, Nasti G, Cassata A, De Stefano A, Caraglia M, Avallone A.

Cancer Lett. 2017 Nov 1;408:71-72. doi: 10.1016/j.canlet.2017.08.025. Epub 2017 Aug 24. No abstract available.

PMID:
28844712
40.

Uncommon neoplasms of the biliary tract: radiological findings.

Granata V, Fusco R Md, Catalano O, Filice S, Avallone A, Piccirillo M, Leongito M, Palaia R, Grassi R, Izzo F, Petrillo A.

Br J Radiol. 2017 Oct;90(1078):20160561. doi: 10.1259/bjr.20160561. Epub 2017 Jul 21.

41.

Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.

Granata V, Fusco R, Catalano O, Avallone A, Palaia R, Botti G, Tatangelo F, Granata F, Cascella M, Izzo F, Petrillo A.

PLoS One. 2017 Jun 20;12(6):e0179951. doi: 10.1371/journal.pone.0179951. eCollection 2017.

42.

Peribiliary liver metastases MR findings.

Granata V, Fusco R, Catalano O, Avallone A, Leongito M, Izzo F, Petrillo A.

Med Oncol. 2017 Jul;34(7):124. doi: 10.1007/s12032-017-0981-7. Epub 2017 Jun 1.

PMID:
28573638
43.

Real-world gastric cancer patients treated with at least three lines of chemotherapy: Outcomes and predictors for efficacy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino S, Melisi D, Antonuzzo L, Pellegrino A, Aprile G.

Ann Oncol. 2017 Jun;28 Suppl 3:iii43-iii44. doi: 10.1093/annonc/mdx261.103. No abstract available.

44.

Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update.

Granata V, Fusco R, Avallone A, Catalano O, Filice F, Leongito M, Palaia R, Izzo F, Petrillo A.

Infect Agent Cancer. 2017 Apr 28;12:23. doi: 10.1186/s13027-017-0132-y. eCollection 2017. Review.

45.

Aseismic transient during the 2010-2014 seismic swarm: evidence for longer recurrence of M ≥ 6.5 earthquakes in the Pollino gap (Southern Italy)?

Cheloni D, D'Agostino N, Selvaggi G, Avallone A, Fornaro G, Giuliani R, Reale D, Sansosti E, Tizzani P.

Sci Rep. 2017 Apr 12;7(1):576. doi: 10.1038/s41598-017-00649-z.

46.

Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.

Ottaiano A, Capozzi M, DE Divitiis C, VON Arx C, DI Girolamo E, Nasti G, Cavalcanti E, Tatangelo F, Romano G, Avallone A, Tafuto S.

Anticancer Res. 2017 Apr;37(4):1975-1978.

PMID:
28373469
47.

Obesity and Cancer: Biological Links and Treatment Implications.

Ottaiano A, De Divitiis C, Capozzi M, Avallone A, Pisano C, Pignata S, Tafuto S.

Curr Cancer Drug Targets. 2018;18(3):231-238. doi: 10.2174/1568009617666170330125619. Review.

PMID:
28359241
48.

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.

Ottaiano A, Capozzi M, De Divitiis C, De Stefano A, Botti G, Avallone A, Tafuto S.

Acta Oncol. 2017 Mar;56(3):377-383. doi: 10.1080/0284186X.2017.1288922. Epub 2017 Feb 17. Review. Erratum in: Acta Oncol. 2017 Mar;56(3):499.

PMID:
28256961
49.

T1 colon cancer in the era of screening: risk factors and treatment.

Bianco F, De Franciscis S, Belli A, Falato A, Fusco R, Altomare DF, Amato A, Asteria CR, Avallone A, Binda GA, Boccia L, Buzzo P, Carvello M, Coco C, Delrio P, De Nardi P, Di Lena M, Failla A, La Torre F, La Torre M, Lemma M, Luffarelli P, Manca G, Maretto I, Marino F, Muratore A, Pascariello A, Pucciarelli S, Rega D, Ripetti V, Rizzo G, Serventi A, Spinelli A, Tatangelo F, Urso ED, Romano GM; Italian Society of Colo-Rectal Surgery (SICCR) Cancer Group.

Tech Coloproctol. 2017 Feb;21(2):139-147. doi: 10.1007/s10151-017-1586-z. Epub 2017 Feb 13.

PMID:
28194568
50.

Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis.

Pecori B, Lastoria S, Caracò C, Celentani M, Tatangelo F, Avallone A, Rega D, De Palma G, Mormile M, Budillon A, Muto P, Bianco F, Aloj L, Petrillo A, Delrio P.

PLoS One. 2017 Jan 6;12(1):e0169462. doi: 10.1371/journal.pone.0169462. eCollection 2017.

Supplemental Content

Loading ...
Support Center